The future of psychedelic-assisted psychotherapy
As the founder of the Multidisciplinary Association for Psychedelic Studies, Rick Doblin crusades for the safe and legal use of psychedelics in therapy.
Since he was 18, Rick Doblin has devoted himself to becoming a legal psychedelic psychotherapist. In 1986, he founded a nonprofit psychedelic pharmaceutical company -- the Multidisciplinary Association for Psychedelic Studies (MAPS) -- which he has grown from a one-man project to an international psychedelic pharmaceutical company.
Doblin's professional goal is to become a legally licensed psychedelic psychotherapist by developing legal contexts for the safe uses of psychedelics and marijuana as prescription medicines and also for personal growth, spirituality and creativity. Today, MAPS is designing or sponsoring psychedelic psychotherapy drug development research in over a dozen countries and has raised more than $70 million in donations.
Doblin received his master's and PhD in public policy from the Kennedy School of Government at Harvard University, and he was in the first group to be certified by Dr. Stanislav Grof as a Holotropic Breathwork practitioner.
Could psychedelic drugs treat PTSD and depression? A Q&A with Rick Doblin
For decades, research into drugs like LSD, MDMA and psilocybin was banned. Now it's time to shed our old fears and fully investigate their potential for treatments that could benefit people with PTSD, depression, substance abuse, and more, says psychedelics expert Rick Doblin.
The future of psychedelic-assisted psychotherapy